Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Size: px
Start display at page:

Download "Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy"

Transcription

1 European Journal of Cardio-Thoracic Surgery 41 (2012) doi: /j.ejcts ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy Tatsuro Okamoto*, Takekazu Iwata, Teruaki Mizobuchi, Hidehisa Hoshino, Yasumitsu Moriya, Shigetoshi Yoshida and Ichiro Yoshino Department of General Thoracic Surgery, Chiba University Graduate School of Medicine, 1-8-1, Inohana, Chuo-ku, Chiba , Japan * Corresponding author. Tel: ; fax: ; tatsurokam@gmail.com (T. Okamoto). Received 21 January 2011; received in revised form 2 April 2011; accepted 7 April 2011 THORACIC Abstract OBJECTIVES: The prognosis of non-small-cell lung cancer (NSCLC) patients with malignant pleural disease (MPD), characterized by malignant pleural effusion and/or malignant pleural nodules, is reported to be poor, and patients with MPD are generally not subjected to surgery. However, whether or not the primary tumor should be resected, when MPD is first detected at thoracotomy, is controversial. METHODS: The clinical records of 1623 consecutive NSCLC patients, who underwent surgery between 1990 and 2007, were retrospectively reviewed. A hundred patients (6.2%) were classified with pathological stage IV disease according to the seventh edition of the Union for International Cancer Control (UICC) staging system. There were 73 patients with MPD, which included 32 with effusion without nodules (MPE) and 41 with nodules with or without effusion (MPN). Intra- or postoperative pleural chemotherapy was administered to 37 MPD patients. RESULTS: The median survival time, the 3-year survival rate and the 5-year survival rate for MPD patients were 25.9 months, 41.4%, and 23.7%, respectively, which are better outcomes than those for M1b patients (8.7 months, 18% and 18%, respectively) (log-lank test: p = 0.014). Among MPD patients, N0 1 disease was determined to be a favorable prognostic factor (p = 0.01). MPD status (MPE or MPN) was not prognostically significant ( p = 0.40). MPE patients with N0 1 disease had a significantly better prognosis with a 5-year survival rate of 63.6% compared to MPE patients with N2 3 disease (p = 0.003). Twenty-seven percent of MPN patients with N0 1 disease achieved 5-year survival, whereas none of the MPD patients with N2 3 disease survived longer than 5 years after surgery. CONCLUSIONS: The prognosis of patients with surgically detected MPD, who underwent resection, was better than that of M1b patients. MPE patients with N0 1 disease may be candidates for resection. Keywords: Lung cancer surgery Pleural space INTRODUCTION Non-small-cell lung cancer (NSCLC) patients with malignant pleural disease (MPD), which includes malignant pleural effusion and/or malignant pleural nodules, are reported to have poor outcomes and are generally considered to be inoperable [1 3]. Analyses of a large patient database from the International Association for the Study of Lung Cancer (IASLC) Staging Project revealed that the median survival time (MST) of patients with MPD discovered during clinical staging was 8 months, and the 5-year survival rate was only 2% [3]. Based on these results, lung cancer patients with malignant pleural effusion/nodules were reclassified to stage IV (M1a) in the new staging system of the Union for International Cancer Control (UICC) [4]. However, NSCLC patients with MPD present with a broad range of disease stages, from minimal disease with little or no pleural effusion that is only detected by examination of pleural lavage fluid, to massive disease with multiple pleural nodules and a large amount of pleural effusion [5]. In clinical practice, pleural disease is sometimes only discovered at thoracotomy, and then it is often controversial whether or not the primary cancer lesion should be removed [6 9]. Generally, patients with minimal pleural dissemination detected only on lavage cytology have been subjected to surgery [4,10]. The treatment of patients with MPD plus sufficient effusion for standard cytological examination or macroscopically detected pleural nodules at thoracotomy is most controversial, because data on these patients are limited [6 10]. The survival data from the IASLC Staging Project for patients, who were pathologically diagnosed with MPD, revealed an MST and a 5-year survival rate of 18 months and 11%, respectively, which is better than the survival data reported for patients with clinically diagnosed MPD [3]. Other researchers have also reported similar favorable results for patients with pathologically diagnosed MPD [6 9]. On the other hand, poor postoperative outcomes have also been demonstrated in patients with malignant pleural effusion [1,10]. In our institution, pleural lavage cytology (PLC) has not been routinely performed. In this study, we reviewed the clinical The Author Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

2 26 T. Okamoto et al. / European Journal of Cardio-Thoracic Surgery records of patients with stage IV disease according to the seventh edition of the UICC staging system, to assess the relevance of pulmonary resection for patients with MPD first detected at thoracotomy by standard histological examination. PATIENTS AND METHODS Patients The clinical records of 1623 consecutive NSCLC patients, who underwent surgery at Chiba University Hospital between 1990 and 2007, were retrospectively reviewed. Among them, 100 patients (6.2%) were classified with pathological stage IV disease according to the seventh edition of the UICC staging system [4]. The mean age at the time of surgery was 62.7 ± 10.9 years. Fifty patients (50%) were male. The median follow-up time was 29.5 months ( months). Histological diagnoses of tumor cell types were based on the World Health Organization histological classification of lung tumors [11]. As many as 80 patients were with adenocarcinoma, 14 with squamous cell carcinoma, 3 with large cell carcinoma, and 3 with adenosquamous cell carcinoma. Standard lobectomies, bilobectomies, pneumonectomies, and partial resections were performed for 74, 11, 5, and 10 patients, respectively. Seventy-five patients (4.6%) had M1a disease, with 73 having MPD and two contralateral pulmonary metastases. We divided MPD into two groups as follows: malignant pleural effusion without nodules (MPE) and malignant pleural nodules with or without effusion (MPN). As many as 32 patients were with MPE and 41 with MPN. A total of 25 patients had M1b disease, with 16 patients having brain metastasis, two bone metastasis, two lymph node metastasis in the neck, and 5 having others. Intra- or postoperative pleural chemotherapy was administered to 37 MPD patients. Intraoperative pleural chemotherapy was administered before closing the chest, and/or postoperative chemotherapy was administered once or twice after operation through the chest tube. During the early study period, mitomycin-c was primarily used for pleural chemotherapy [9], and thereafter cisplatin was used. A total of 25 patients received postoperative adjuvant cisplatin-based chemotherapy. This observational study was approved by the Institutional Review Board of Chiba University Hospital, Chiba, Japan. Statistical analysis Intergroup differences in patient characteristics, including age, gender, cell type, tumor size, and procedure, were assessed using the Student s t-test and χ 2 -test. The Kruskal Wallis test was used to compare the nodal status of the three patient groups (MPE, MPN, and M1b). Survival curves were estimated by the Kaplan Meier method, and significance was assessed by the log-rank test. The terminal event was death from any cause. Univariate survival analysis was performed using the Cox proportional hazards model. For multivariate survival analysis, variables, including age, gender, and procedure, were further analyzed in a stepwise manner. Statistical differences were considered to be significant for p values less than All data were analyzed using Abacus Concepts, Survival Tools for StatView version 5.0 (Abacus Concepts, Inc., Berkeley, CA, USA). RESULTS Patient characteristics and survival in stage IV patients Patient characteristics are described in Table 1. Patients with contralateral lung metastases, who were included in the M1a group, were excluded from this analysis because of the low number of these patients (n = 2). There were no significant differences between the three patient groups, except for gender. Table 1: Clinical and pathological characteristics in patients with malignant pleural disease or M1b disease MPE MPN M1b p-value n % n % n % Number Age (y) Mean 63.7 (SD 9.6) 62.4 (SD 10.9) 61.5 (SD 12.5) 0.51 Gender Male Female Histology Adenocarcinoma Squamous cell Large cell Adenosquamous Tumor size <3 cm >3 cm Nodal status N N N N Procedure Partial resection Lobectomy Bilobectomy Pneumonectomy MPE = malignant pleural effusion without nodules; MPN = malignant pleural nodules with or without effusion.

3 T. Okamoto et al. / European Journal of Cardio-Thoracic Surgery 27 Table 2: Univariate analysis for prognostic factors in patients with malignant pleural disease n MST HR 95% CI p-value Age (y) < > Gender Male Female Histology Adenocarcinoma Non-adeno Tumor size 3 cm >3 cm Nodal status N N Procedure Other Pneumonectomy Pleural disease MPE MPN THORACIC CI = confidence interval, HR = hazard ratio. MST = median survival time, MPE = malignant pleural effusion without nodules, MPN = malignant pleural nodules with or without effusion. Table 3: Multivariate analysis for prognostic factors in patients with malignant pleural disease HR 95% CI p-value Figure 1: (A) Postoperative survival curves of patients with malignant pleural disease (MPD) and patients with distant metastasis (M1b); (B) postoperative survival curves of patients with malignant pleural effusion without nodules (MPE), patients with malignant pleural nodules with or without effusion (MPN) and patients with distant metastasis (M1b). (MST = median survival time). Significantly more male patients existed in the M1b group compared to the other groups ( p = ). Most of the MPD cancers were adenocarcinomas (90.6% MPE and 80.5% MPN), whereas 24% of the M1b cancers were squamous cell carcinomas. Approximately half of the MPD patients had tumors less than 3 cm in size (50% of MPE and 51.2% of MPN patients). The proportions of MPE and MPN patients with N0 1 status were 43.8% and 48.7%, respectively. The MST of all patients (n = 100) with pathological stage IV disease according to the seventh edition of the UICC staging system was 24.3 months. The 3-year and 5-year survival rates were 25.2% and 22.2%, respectively. The survival curves of patients with MPD (n = 73) and M1b (n = 25) disease are shown in Fig. 1A. The MST, the 3-year survival rate, and the 5-year survival rate were 25.9 months, 41.4%, and 23.7%, respectively, in the MPD patients, and 8.7 months, 18%, and 18%, respectively, in the M1b patients. The difference in overall survival was significant (long-rank test: p = 0.014), although there appeared to be little difference in long-term survival. Survival of patients with MPD Results of univariate survival analyses using the Cox proportional hazards model are shown in Table 2. Although MPD status (MPE or MPN) was not significant, the N status (N0 1 vsn2 3) and Age (y) <65 1 > Gender Male 1 Female Nodal status NO 1 1 N Procedure Others 1 Pneumonectomy Pleural disease MPE 1 MPN CI = confidence interval, HR = hazard ratio. MST = median survival time, MPE = malignant pleural effusion without nodules, MPN = malignant pleural nodules with or without effusion. type of surgical procedure ( pneumonectomy vs other procedures) were found to be significant prognostic factors, and these results were confirmed by multivariate analysis (Table 3). In comparison with stage IV M1b patients, MPE patients had significantly better survival ( p = 0.015) and MPN patients had a more favorable prognosis (p = 0.054) (Fig. 1B). The MST, the 3-year survival rate and the 5-year survival rate were 26.1 months, 43.1%, and 37.7%, respectively, in the MPE patients, and 25.9 months, 39.9%, and 14.8%, respectively, in the MPN patients. The survival curves of MPD patients stratified by N status (N0 1 vs N2 3) are shown in Fig. 2A and demonstrate a significant difference between the two categories (log-rank test: p = 0.003). We further divided these groups into four categories according to MPD status (Fig. 2B). MPE patients with N0 1 status (n = 14) had the best survival, with a 5-year survival of 63.6%, which is significantly better than MPE patients with N2 3 status (p = 0.011). Although the outcomes of MPN patients with N0 1 status were not as good as the outcomes of the MPE N0 1 group, 27.3% of these MPN patients achieved long-term survival

4 28 T. Okamoto et al. / European Journal of Cardio-Thoracic Surgery whereas none of the MPD patients with N2 3 status survived longer than 5 years after surgery. DISCUSSION In the seventh edition of the UICC lung cancer staging system, patients with MPD, which includes malignant pleural effusion Figure 2: (A) Postoperative survival curves of patients with malignant pleural disease (MPD) according to N status; (B) postoperative survival curves of patients with malignant pleural effusion without nodules (MPE) and patients with malignant pleural nodules with or without effusion (MPN) stratified by N status. (MST = median survival time). and/or malignant pleural nodules, were reclassified from stage IIIB (T4) to stage IV (M1a). The IASLC Lung Cancer Staging Project reported that patients with clinical MPD had a dismal prognosis, with an MST of 8 months and a 2% 5-year survival rate [3]. Although clinically diagnosed MPD patients generally present with a fair amount of malignant pleural effusion [5], MPD that is first encountered at thoracotomy usually has less effusion or fewer pleural nodules, both of which were not definitively detected by preoperative examinations [8]. Therefore, a subgroup of patients with minimal pleural disease may be at an earlier stage of cancer progression in the pleural cavity. There have been a series of papers investigating the survival of patients with pleural disease detected by PLC. Although this group was reported to have a worse outcome than those patients without pleural disease [12 14], they have not been classified as MPD patients and surgical treatment has been generally undertaken even if the cytology is confirmed positive before resection. Recently, the International Pleural Lavage Cytology Collaborators performed a pooled data analysis on the survival of surgical patients with positive PLC [15]. In this analysis, the overall 1- and 5-year survival rates of positive PLC patients were 80% and 31%, respectively. They concluded that the impact of positive PLC on survival was equivalent to a single increase in the T category. The IASLC Staging Project showed that pathologically staged MPD patients, most of whom were surgically treated, had an MST and 5-year survival rate of 18 months and 11%, respectively [3]. These outcomes were better than those for the clinically staged MPD patients mentioned previously. Since 2000, there have been five relatively large studies, including a former study at our institution, investigating more than 43 surgical MPD patients (Table 4). Ichinose et al. [6] gathered data on 227 surgically treated MPD patients from 21 institutions registered with the Japan Clinical Oncology Group ( JCOG). The survival results of this study are very similar to the results from the IASLC. In addition, none of the 34 patients, who did not undergo resection of the primary lesion, survived for more than 5 years after thoracotomy. Similar results were reported by Fukuse et al. [8]. By contrast, unfavorable survival was demonstrated in the study reported by Sawabata et al. They investigated patients with minor malignant pleural effusion, with volumes less than 300 ml [10]. They did not observe any survival benefits for resection of the primary lesion compared to incomplete resection or Table 4: Summary of studies since 2000 of surgically treated patients with malignant pleural disease Author Year Patients n Survival Prognostic factors MST (months) 3-Y (%) 5-Y (%) Ichinose 2000 MPD N factor Macroscopic residual tumor Ohta 2000 MPN Cell type Shiba 2001 MPD 65 NA NA 14.3 Ki-67 labeling index N factor Tumor differentiation Fukuse 2001 MPD Pleural nodules T factor Sawabata 2002 MPE NA 5 NA This study MPD N factor MPD = malignant pleural disease; MPE = malignant pleural effusion without nodules, MPN #= malignant pleural nodules with or without effusion; MST = Median survival time; NA = not available; Y = year.

5 T. Okamoto et al. / European Journal of Cardio-Thoracic Surgery 29 exploratory thoracotomy. In the present study, the outcomes of MPD patients were better than the historical outcomes, with an MST of 25.9 months, and 3-year and 5-year survival rates of 41.4% and 23.7%, respectively. These outcomes were also significantly better than those of the surgically treated M1b patients. Pleural chemotherapy was performed in half of our patients, and one-third of the patients underwent postoperative adjuvant chemotherapy. These postoperative treatments may have played a role in these favorable outcomes. In addition, patients who did not undergo pulmonary resection were not included in this series. Preoperative selection of surgical patients may have contributed in part to the results, although pulmonary resection was primarily undertaken after encountering MPD at thoracotomy. In the JCOG study [6], findings of adenocarcinoma, no clinical lymph node metastases, and no macroscopic residual tumors were demonstrated to be prognostic factors for better outcomes. Patients with these three factors had a promising 5-year survival rate of 24%. In another JCOG study, 100 patients with minimal MPD consisting of MPE of less than 300 ml or few malignant pleural nodules were investigated [16]. The 3-year and 5-year survival rates were 31.8% and 22.8%, respectively, results similar to those for resected patients with positive PLC. The subset analysis from Fukuse et al. [8] demonstrated that patients with MPE had significantly better outcomes than patients with malignant pleural nodules (hazard ratio HR 3.24, 95% confidence interval , p = 0.015), and they suggested that selected patients with small MPE volumes may have significant benefits from surgical resection. In the present study, multivariate analysis revealed that pneumonectomy and N status were significant prognostic factors in MPD patients, although no differences were seen between the two types of MPD (MPE vs MPN). Regarding surgical procedures, patients who underwent pneumonectomy had much worse outcomes than those who underwent less resection. Because only three patients underwent pneumonectomy, the significance of this prognostic factor should be regarded with caution. One reason for the poor outcomes may be that patients who underwent pneumonectomy had more advanced disease than the other patients; two out of three patients actually had N2 disease. No prognostic difference was seen for the other surgical procedures, including lobectomy, which was performed for the majority of our MPD patients (75%). Regarding lymph node status in our study, for all MPD patients, N0 1 patients had significantly better outcomes than N2 3 patients. Similar results were reported from two previous studies [6,9]; however, they demonstrated a survival advantage for node-negative patients (N0) compared with node-positive patients (N1 3). In the present study, the prognostic significance was larger for the combined N0 and N1 group than for N0 alone (data not shown). In the JCOG study [6], the percent of patients undergoing lobectomy was 64%, which is lower than the percent of our patients undergoing lobectomy and bilobectomy (85%), and this may account for the different study results. If this result is confirmed, it may be reasonable to choose lobectomy as the surgical treatment for MPD patients. When MPD patients were divided into MPE and MPN groups, which were further divided according to nodal status, the outcomes of N0 1 patients with MPE were much better than the outcomes of the other groups, with an MST of longer than 5 years. One possible explanation for this unexpected, good outcome is that there may have been patients who had malignant cells only in the pleural effusion but not on the parietal pleura. In such patients, especially those with early N status, cancer cells could have been completely removed by the surgical procedure. In the MPN patients, no significant difference was seen between the two nodal-status groups; however, the 5-year survival rate for N0 1 patients was greater than 20%, which appears to be a better outcome compared to the outcome for N2 3 patients with MPN where no patient was alive 5 years after operation. There are limitations to our study, because it is a retrospective analysis based on assessable historical data. A randomized prospective study is needed to confirm the effect of surgery for MPD patients; however, the results of this study suggest that resection of the primary site can be considered for MPE patients with N0 1 status. In addition, among MPN patients with N0 1 status, there are patients who also achieve long-term survival after pulmonary resection. ACKNOWLEDGEMENTS The authors thank Professor Makoto Suzuki of the Department of Thoracic Surgery, Graduate school of Medicine, Kumamoto University, for his kind review of this article. Conflict of interest: none declared. REFERENCES [1] Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997;3: [2] Jett JR, Scott WJ, Rivera MP, Sause WT, American College of Chest Physicians. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest 2003;123:221S 5S. [3] Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L, International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: [4] Sobin LH, Gospodarowicz MK, Wittekind C, International Union Against Cancer. TNM classification of malignant tumours, 7th ed., Oxford, UK: Wiley-Blackwell; p [5] Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008;83: [6] Ichinose Y, Tsuchiya R, Koike T, Kuwahara O, Nakagawa K, Yamato Y, Kobayashi K, Watanabe Y, Kase M, Yokoi K, Japan Clinical Oncology Group. The prognosis of patients with non-small cell lung cancer found to have carcinomatous pleuritis at thoracotomy. Surg Today 2000;30: [7] Ohta Y, Tanaka Y, Hara T, Oda M, Watanabe S, Shimizu J, Watanabe Y. Clinicopathological and biological assessment of lung cancers with pleural dissemination. Ann Thorac Surg 2000;69: [8] Fukuse T, Hirata T, Tanaka F, Wada H. The prognostic significance of malignant pleural effusion at the time of thoracotomy in patients with nonsmall cell lung cancer. Lung Cancer 2001;34: [9] Shiba M, Kakizawa K, Kohno H, Shibuya K, Yamakawa H, Hiroshima K, Fujisawa T. Prognostic implication of Ki-67 immunostaining in treating subclinical pleural cancer found at thoracotomy in lung cancer patients. Ann Thorac Surg 2001;71: [10] Sawabata N, Matsumura A, Motohiro A, Osaka Y, Gennga K, Fukai S, Mori T, Japanese National Chest Hospital Study group for Lung Cancer. Malignant minor pleural effusion detected on thoracotomy for patients with non-small cell lung cancer: is tumor resection beneficial for prognosis?. Ann Thorac Surg 2002;73: THORACIC

6 30 T. Okamoto et al. / European Journal of Cardio-Thoracic Surgery [11] Travis WB, Brambilla E, Muller-Hermelink HK, Harris CC, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung. Pleura, Thymus and Heart. Lyon: IARC Press; [12] Okada M, Sakamoto T, Nishio W, Uchino K, Tsuboshima K, Tsubota N. Pleural lavage cytology in non-small cell lung cancer: lessons from 1000 consecutive resections. J Thorac Cardiovasc Surg 2003;126: [13] Lim E, Ali A, Theodorou P, Nicholson AG, Ladas G, Goldstraw P. Intraoperative pleural lavage cytology is an independent prognostic indicator for staging non-small cell lung cancer. J Thorac Cardiovasc Surg 2004;127: [14] Vicidomini G, Santini M, Fiorello A, Parascandolo V, Calabrò B, Pastore V. Intraoperative pleural lavage: is it a valid prognostic factor in lung cancer? Ann Thorac Surg 2005;79: [15] International Pleural Lavage Cytology Collaborators. Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: an international individual patient data meta-analysis. J Thorac Cardiovasc Surg 2010;139: [16] Ichinose Y, Tsuchiya R, Koike T, Kuwahara O, Nakagawa K, Yamato Y, Kobayashi K, Watanabe Y, Kase M, Yokoi K, Japan Oncology Group. Prognosis of resected non-small cell lung cancer patients with carcinomatous pleuritis of minimal disease. Lung Cancer 2001;32:55 60.

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma 244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA

More information

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

Prognosis of non-small-cell lung cancer patients with positive pleural lavage cytology

Prognosis of non-small-cell lung cancer patients with positive pleural lavage cytology Interactive CardioVascular and Thoracic Surgery 20 (2015) 777 782 doi:10.1093/icvts/ivv047 Advance Access publication 11 March 2015 ORIGINAL ARTICLE THORACIC Cite this article as: Nakao M, Hoshi R, Ishikawa

More information

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution

Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Visceral pleural invasion (VPI) of lung cancer has been

Visceral pleural invasion (VPI) of lung cancer has been ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*

More information

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer

Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer Original Article Complete resection of the primary lesion improves survival of certain patients with stage IV non-small cell lung cancer Yasuhiro Chikaishi, Shinji Shinohara, Taiji Kuwata, Masaru Takenaka,

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

Lung cancer is one of the leading causes of death in most

Lung cancer is one of the leading causes of death in most ORIGINAL ARTICLE Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD,* Etsuo Miyaoka, PhD, Hisao Asamura, MD, PhD,

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J.

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J. Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,

More information

The T4 category of lung cancer is defined by invasion of the

The T4 category of lung cancer is defined by invasion of the Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Segmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute

Segmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute Segmentectomy for selected ct1n0m0 non small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, a Takeshi Mori, PhD, b Koei Ikeda, PhD, b Kentaro Yoshimoto, PhD, b Kenichi

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Lung cancer is now a major cause of death in developed

Lung cancer is now a major cause of death in developed Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,

More information

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,

More information

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer European Journal of Cardio-Thoracic Surgery 49 (2016) 580 588 doi:10.1093/ejcts/ezv134 Advance Access publication 18 April 2015 ORIGINAL ARTICLE Cite this article as: Lee GD, Kim DK, Moon DH, Joo S, Hwang

More information

Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients

Prognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients 1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,

More information

Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma

Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma /, 2017, Vol. 8, (No. 42), pp: 73115-73122 Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma Ying He 1,*, Yong Cui 1,*, Dong Chang 1 and Tianyou Wang

More information

There has been a growing interest in lung cancer in neversmokers,

There has been a growing interest in lung cancer in neversmokers, ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*

More information

Lung cancer involving neighboring structures is classified

Lung cancer involving neighboring structures is classified GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka,

More information

Prognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology

Prognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology Int Surg 2014;99:830 834 DOI: 10.9738/INTSURG-D-14-00119.1 Prognostic Role of Gastrectomy in Patients With Gastric Cancer With Positive Peritoneal Cytology Okihide Suzuki, Minoru Fukuchi, Erito Mochiki,

More information

Lung cancer is the leading cause of cancer deaths worldwide.

Lung cancer is the leading cause of cancer deaths worldwide. ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu

More information

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer

Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules

Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA

More information

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu

More information

Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma

Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma BioMed Research International, Article ID 64568, 6 pages http://dx.doi.org/.55/24/64568 Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically

More information

Lung cancer is the most common cause of cancer-related

Lung cancer is the most common cause of cancer-related Original Article Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita, MD,* Takashi Ohtsuka, MD, PhD,*

More information

Prognostic Significance of Carcinoembryonic Antigen Level in Pleural Lavage Fluid for Patients With Lung Adenocarcinoma

Prognostic Significance of Carcinoembryonic Antigen Level in Pleural Lavage Fluid for Patients With Lung Adenocarcinoma Prognostic Significance of Carcinoembryonic Antigen Level in Pleural Lavage Fluid for Patients With Lung Adenocarcinoma Masaki Tomita, MD, PhD, Tetsuya Shimizu, MD, PhD, Yasunori Matsuzaki, MD, PhD, Masaki

More information

Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification

Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

The 7th Edition of TNM in Lung Cancer.

The 7th Edition of TNM in Lung Cancer. 10th European Conference Perspectives in Lung Cancer. Brussels, March 2009. The 7th Edition of TNM in Lung Cancer. Peter Goldstraw, Consultant Thoracic Surgeon, Royal Brompton Hospital, Professor of Thoracic

More information

Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion

Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion Received: 1 May 2016 Revised: 19 June 2016 Accepted: 10 July 2016 DOI: 10.1111/crj.12527 ORIGINAL ARTICLE Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

The prognostic significance of central fibrosis of adenocarcinoma

The prognostic significance of central fibrosis of adenocarcinoma Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji

More information

The International Association for the Study of Lung

The International Association for the Study of Lung ORIGINAL ARTICLE Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer A Comprehensive Analysis of 26,957 Patients with NSCLC Tomoya

More information

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma

Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:

More information

MOLECULAR AND CLINICAL ONCOLOGY 1: , 2013

MOLECULAR AND CLINICAL ONCOLOGY 1: , 2013 MOLECULAR AND CLINICAL ONCOLOGY 1: 437-443, 2013 Clinicopathological features and the impact of the new TNM classification of malignant tumors in patients with pulmonary large cell neuroendocrine carcinoma

More information

Small cell lung cancer (SCLC), which represents 20%

Small cell lung cancer (SCLC), which represents 20% ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,

More information

A new scoring system for peritoneal metastasis in gastric cancer

A new scoring system for peritoneal metastasis in gastric cancer Gastric Cancer (2003) 6: 146 152 DOI 10.1007/s10120-003-0243-6 2003 by International and Japanese Gastric Cancer Associations Original article A new scoring system for peritoneal metastasis in gastric

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

RESEARCH ARTICLE. Masaki Tomita 1, Takanori Ayabe 1, Eiichi Chosa 1, Naohiro Nose 1, Kunihide Nakamura 2 * Abstract. Introduction

RESEARCH ARTICLE. Masaki Tomita 1, Takanori Ayabe 1, Eiichi Chosa 1, Naohiro Nose 1, Kunihide Nakamura 2 * Abstract. Introduction RESEARCH ARTICLE Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer Masaki Tomita 1, Takanori

More information

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy

Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication

More information

Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule

Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,

More information

GTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 3 607

GTS. The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 3 607 Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter

More information

After primary tumor treatment, 30% of patients with malignant

After primary tumor treatment, 30% of patients with malignant ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer

Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non small cell lung cancer Terumoto Koike, MD, PhD, a,b Teruaki Koike, MD, PhD, a Katsuo Yoshiya,

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer

Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer Clinicopathological Characteristics and Outcome Indicators of Stage II Gastric Cancer According to the Japanese Classification of Gastric Cancer HITOSHI OJIMA 1, KEN-ICHIRO ARAKI 1, TOSHIHIDE KATO 1, KAORI

More information

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis

Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,

More information

Invasion to the visceral pleura is an important component

Invasion to the visceral pleura is an important component Diagnosis of Visceral Pleural Invasion by Lung Cancer Using Intraoperative Touch Cytology Yushi Saito, MD, PhD, Yosuke Yamakawa, MD, PhD, Masanobu Kiriyama, MD, PhD, Ichiro Fukai, MD, PhD, Satoshi Kondo,

More information

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce

More information

Lung cancer is a prevalent health problem worldwide. It is the leading cause

Lung cancer is a prevalent health problem worldwide. It is the leading cause Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying

More information

Peritoneal Involvement in Stage II Colon Cancer

Peritoneal Involvement in Stage II Colon Cancer Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.

More information

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,

More information

Prognosis of recurrent non small cell lung cancer following complete resection

Prognosis of recurrent non small cell lung cancer following complete resection 1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI

More information

Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis?

Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Pleomorphic carcinoma of the lung: which CT findings predict poor prognosis? Poster No.: C-1887 Congress: ECR 2015 Type: Scientific Exhibit Authors: A. Fujisaki, T. Aoki, S. Kinoshita, Y. Hayashida, Y.

More information

Multifocal Lung Cancer

Multifocal Lung Cancer Multifocal Lung Cancer P. De Leyn, MD, PhD Department of Thoracic Surgery University Hospitals Leuven Belgium LEUVEN LUNG CANCER GROUP Department of Thoracic Surgery Department of Pneumology Department

More information

Pulmonary resection for metastatic colorectal carcinoma was first performed

Pulmonary resection for metastatic colorectal carcinoma was first performed General Thoracic Surgery Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment Yukihito Saito, MD, a Hideyasu Omiya, MD, a Keijiro Kohno, MD, b Takanobu Kobayashi,

More information

Xiang Hu*, Liang Cao*, Yi Yu. Introduction

Xiang Hu*, Liang Cao*, Yi Yu. Introduction Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang

More information

Cytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer

Cytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer Cytologically Malignant Margins of Wedge Resected Stage I Non-Small Cell Lung Cancer Noriyoshi Sawabata, MD, Akihide Matsumura, MD, Mitsunori Ohota, MD, Hajime Maeda, MD, Hiroshi Hirano, MD, Katsuhiro

More information

Surgery remains the mainstay treatment for localized

Surgery remains the mainstay treatment for localized Surgical Results in T2N0M0 Nonsmall Cell Lung Cancer Patients With Large Tumors 5 cm or Greater in Diameter: What Regulates Outcome? Yasuhiko Ohta, MD, Ryuichi Waseda, MD, Hiroshi Minato, MD, Naoki Endo,

More information

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*

Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi

More information

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal

Non small cell lung cancer (NSCLC) with ipsilateral mediastinal Results of surgical intervention for p-stage IIIA (N2) non small cell lung cancer: Acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper

More information

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD

Accepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:

More information